Contrasting Plus Therapeutics (NASDAQ:PSTV) and Inspira Technologies Oxy B.H.N. (NASDAQ:IINN)

Inspira Technologies Oxy B.H.N. (NASDAQ:IINN) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Earnings & Valuation

This table compares Inspira Technologies Oxy B.H.N. and Plus Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspira Technologies Oxy B.H.N.	N/A	N/A	-$11.29 million	N/A	N/A
Plus Therapeutics	$4.91 million	1.41	-$13.32 million	($2.53)	-0.46

Inspira Technologies Oxy B.H.N. has higher earnings, but lower revenue than Plus Therapeutics.

Profitability

This table compares Inspira Technologies Oxy B.H.N. and Plus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inspira Technologies Oxy B.H.N.	N/A	N/A	N/A
Plus Therapeutics	-225.07%	N/A	-144.58%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Inspira Technologies Oxy B.H.N. and Plus Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspira Technologies Oxy B.H.N.	0	0	0	0	0.00
Plus Therapeutics	0	0	2	0	3.00

Plus Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 1,096.58%. Given Plus Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Inspira Technologies Oxy B.H.N..

Volatility & Risk

Inspira Technologies Oxy B.H.N. has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

Institutional & Insider Ownership

12.7% of Inspira Technologies Oxy B.H.N. shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 29.4% of Inspira Technologies Oxy B.H.N. shares are held by insiders. Comparatively, 5.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Inspira Technologies Oxy B.H.N. beats Plus Therapeutics on 6 of the 10 factors compared between the two stocks.

About Inspira Technologies Oxy B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.

About Plus Therapeutics

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.